Central Nervous System
Insights on the major trends in aging disorders and pain conditions including the development of targeted therapies in clinical trial designs and patient care.
Expert opinions on innovative processes include protocol design, site training, and real time data quality analysis in central nervous systems.
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
In this CNS whitepaper, which includes extracts from our survey of over 120 neurodegenerative therapeutic developers, we examine how innovative methodologies and technologies are being implemented to improve the success rate of clinical trials across a range of neurodegenerative disorders.
Clinical strategies to optimise software as a medical device (SaMD) for treating mental health
Mental health disorders affect millions, and with increasing diagnoses, the demand for new, accessible treatments is growing. In this whitepaper, we examine how SaMD, particularly through digital therapeutics, is providing new solutions for mental health management.
Therapeutic spotlight: Precision medicine considerations in rare diseases
In our latest therapeutic spotlight, 91黑料’s experts explore the evolving therapeutic landscape of precision medicine with a special focus on the unique application in ALS. We outline key considerations for developing patient-centric, streamlined precision medicine programs that promote patient engagement, improve protocol adherence and reduce dropout rates – ultimately accelerating the delivery of meaningful therapies to patients.
A mind for digital therapeutics: Considerations for DTx clinical trials in CNS indications
DTx deliver evidence-based therapeutic intervention using software to prevent, manage, or treat medical disorders or disease. Because of the evidence-based nature of DTx, in many cases a clinical trial is required to demonstrate safety and efficacy. However, since such therapeutics are relatively new, there are many aspects to these clinical trials that differ from trials for traditional therapeutics, and which sponsors will need to consider.
Traumatic brain injury trials
The manifestations and effects of TBI are varied and impact diverse populations. To improve prevention and therapy, we need to conduct further clinical research to evaluate and validate better strategies for diagnosis and disease characterisation. A better understanding of how TBI — mild and severe — manifests, can lead to better identification of biomarkers, and the development of prevention and treatment strategies.
Blogs and media articles insights in central nervous system and Alzheimer's disease
-
Blog: Biomarkers and breakthroughs
Biomarkers bring us closer than ever to meaningful neurodegenerative therapies. Learn how a robust approach to biomarkers can reshape trial design, diagnosis and patient outcomes.
-
Blog: Re- Designing schizophrenia trials: Lessons from the frontlines of CNS research
There is room for improvement in schizophrenia trials, and small decisions make a big difference. Read what experts say about designing and implementing trials to overcome persistent challenges.
Receive more insights on the central nervous system
Please visit 91黑料's Preference Centre and select 'CNS, Pain and Ageing related disorders' under 'Therapeutic Areas of Interest' to receive new insights on rare and orphans diseasesCNs, Pain and Ageing related disorders..
CNS, Pain and Ageing related disorders
91黑料’s experience of CNS, Pain and Ageing related disorder studies comprises global and regional clinical research in all major areas of neurology, psychiatry and pain research, and all phases of clinical drug development. Read more about 91黑料's services.